CapitolRadar tracks every publicly disclosed PCVX trade by US congress members and corporate insiders: 2 disclosed trades (2 buys, 0 sells) by 1 tracked traders, from 2026-07-15 to 2026-07-16. Updated daily from official filings.
Want a ping when Congress buys PCVX? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Vaxcyte, Inc. (PCVX) — Healthcare · Biotechnology, market cap about $10.4B.
Cluster watch: 3 distinct tracked traders disclosed buying PCVX in the last 45 days: Jodar Luis (officer: Chief Medical Officer), Wassil Jim (officer: EVP, Chief Scientific Ofc, COO), Cowan Elvia (officer: SVP, Finance & CAO).
CapitolRadar analysis
2 PCVX buys across a 2-day window
2 tracked Vaxcyte, Inc. (PCVX) trades appear from July 15 through July 16, 2026. Both were buys, with 0 sells, so the disclosed activity is one-sided within this narrow window. The full set falls in 2026 Q3 and involves 1 distinct trader. Because the sample consists of only 2 transactions from a single person, it does not establish a broad pattern across multiple filers.
1 buyer accounts for all tracked activity
Gilbert Cisneros made both tracked PCVX buys, with the latest dated July 16, 2026. No other buyer or seller is represented in the supplied PCVX data. The result is concentrated participation: 100% of the tracked trades and 100% of the buys came from the same disclosed trader. PCVX is classified in the Healthcare sector and Biotechnology industry.
6 other stocks appear in the buyer’s disclosed buying activity
The tracked buyer also bought AMD, HLI, USPH, ABCB, EPAC and SFM. Since there is only 1 PCVX buyer in this dataset, each “1 of them” overlap refers to that entire but very small buyer cohort. The supplied facts do not provide transaction values, portfolio weights, timing for those other purchases or reasons for any trade, so the overlaps show disclosed co-buying only and should not be read as evidence of a specific strategy.
Disclosure data can be reported with a lag of up to 45 days, so trade dates and public availability may differ materially. Transaction amounts, when presented as disclosure ranges, are estimates rather than exact purchase values; no amount ranges are included in the supplied PCVX facts. The limited count, short date span and single-trader sample all constrain broader interpretation.
Analysis written from the tracked record on 2026-09-10; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 2 | 2 | 0 |
Who is buying PCVX?
| Trader | Disclosed buys | Last buy | Grade |
|---|---|---|---|
| Gilbert Cisneros | 2 | 2026-07-16 | — |
Disclosed trades in PCVX
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-07-16 | Gilbert Cisneros | buy | $1,001 - $15,000 | — |
| 2026-07-15 | Gilbert Cisneros | buy | $1,001 - $15,000 | — |
CapitolRadar signal history
NEW PICK 2026-09-09
Rep. Gilbert Ray Cisneros disclosed buying $1,001 to $15,000 of Vaxcyte (PCVX) stock. The panel passed mainly because he has no verified trading history versus SPY, so this purchase is an unproven signal; a documented record of strong results on similar trades could have changed the verdict. The biggest caveat is the 54-day disclosure delay, which makes the purchase less timely to evaluate.
These buyers also bought
Other stocks the tracked buyers of PCVX disclosed buying in the last six months: BHE (1) · FERG (1) · MRVL (1) · SFM (1) · YETI (1) · ATRC (1).
About Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and …
Frequently asked questions
Which politicians bought PCVX most?
Gilbert Cisneros leads with 2 disclosed buys.
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.